There is a possibility that Gilead Sciences, Inc. (NASDAQ:GILD) may offer $45 billion to acquire Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in an attempt to tap into the cystic fibrosis market. We at Bidness Etc, however, believe that Corbus Pharmaceuticals Holding Inc’s (NASDAQ:CRBP) plans to begin Phase II trials for an experimental cystic fibrosis drug may slow down Gilead’s plans to extend an acquisition offer.
Vertex may find its star drug Kalydeco facing competition in the market, as Corbus Pharmaceuticals posts impressive trial results for Resunab, an experimental drug designed to treat cystic fibrosis.
Hey, check out all the research scientist jobs. Post your resume today!
